Yellow Fever
Recent clinical, regulatory, research and industry developments relating to this disease.
Emerging and Re-emerging Vector-Borne Infectious Diseases and the Challenges for Control: A Review.
Climate change and mosquito-borne disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q3 2026.
Clinical MilestonesViewHide
- 2026-06-01Yellow Fever Vaccine Immunity After 1 Dose of Vaccine in Children and Adults: a Cohort Study in Non-endemic AreaPrimary completion
- 2026-01-20A Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 YearsCompleted
- 2025-12-25A Phase 3, Single Arm, Open Study to Assess the Immunogenicity and Safety of vYF in Adults Aged 18 Years and OverCompleted
- 2025-11-01A Phase I/II Study Of The Immunogenicity Of The Yellow Fever Vaccine 17D (YFVax®) In Adults With Prior 17D VaccinationPrimary completion
- 2026-06-01ClinicalYellow Fever Vaccine Immunity After 1 Dose of Vaccine in Children and Adults: a Cohort Study in Non-endemic AreaPrimary completion
- 2026-05-06ClinicalA Parallel Group, Phase III Randomized, Modified Double-blind, Active Controlled Study to Investigate the Immunogenicity and Safety of vYF Compared to Licensed YF Vaccines in Pediatric Population Aged 9 Months to 5 Years of AgeResults expected Q3 2026
- 2026-01-20ClinicalA Phase 3 Randomized, Modified Double-blind, Active-controlled Study to Assess the Safety of vYF, Yellow Fever Vaccine, in Adults Aged 18 Years up to 60 YearsCompleted
- 2025-12-25ClinicalA Phase 3, Single Arm, Open Study to Assess the Immunogenicity and Safety of vYF in Adults Aged 18 Years and OverCompleted
- 2025-11-01ClinicalA Phase I/II Study Of The Immunogenicity Of The Yellow Fever Vaccine 17D (YFVax®) In Adults With Prior 17D VaccinationPrimary completion
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Chikungunya Fever1
- Communicable Diseases, Emerging1
- Culicidae1
- Disease Transmission, Infectious1
- Greenhouse Effect1
- Insect Vectors1
- Vector Borne Diseases1
- Yellow Fever1
Leading journals2
- Environmental health perspectives1
- Frontiers in public health1
Leading researchers3
- Chala B1
- Hamde F1
- Reiter P1
Affiliations (unnormalised)2
- National Center for Infectious Diseases1
- School of Applied Natural Science1
Reference
Authoritative identity, definition & identifiers.
An acute infectious disease primarily of the tropics, caused by a virus and transmitted to man by mosquitoes of the genera Aedes and Haemagogus. The severe form is characterized by fever, HEMOLYTIC JAUNDICE, and renal damage.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.